This MNC Pharma Stock Rises 87% in 3 Years: What Powered the Rally?

This MNC pharma stock has turned Rs 1 lakh into roughly Rs 1.87 lakh over the past three years, without taking on debt or diluting shareholders. The share delivered a 3-year return of 87.41% as of 10 September 2026, ranking 49th in a screen of 101 large-cap and mid-cap NSE shares.

The company is GlaxoSmithKline Pharmaceuticals Ltd (NSE: GLAXO), the Indian listed arm of the British drugmaker GSK plc, which owns 75% of it. The GSK Pharma share closed at approximately Rs 2,841 on 10 September 2026, down about 1.57% for the day, giving the company a market value of around Rs 48,100 crore. It sells household antibiotic brands such as Augmentin and Ceftum, respiratory drugs like Nucala and Trelegy, and vaccines including Shingrix.

Click Here – Get Free Investment Predictions

How Much Has This MNC Pharma Stock Returned Across Time Frames?

This MNC pharma stock has returned 87.41% in three years and 95.88% in five years. The shorter periods are mixed: the share is up 25.94% in six months and 11.61% in one month, but only 9.15% over one year, where it ranks 75th, in the bottom half of the screen.

Here is how the MNC pharma stock ranks across periods within the 101-stock screen:

Period	Return (%)	Rank (out of 101)
1 Month	11.61%	17
6 Months	25.94%	54
1 Year	9.15%	75
3 Years	87.41%	49
5 Years	95.88%	56

Returns are simple price changes and are not annualised. For this MNC pharma stock, there was no stock split or bonus issue in the three-year window, so the 87% gain is genuine price appreciation. Working back from the latest close, the MNC pharma stock traded near Rs 1,516 in September 2023.

The path was not smooth. The GSK Pharma share price hit an all-time high of about Rs 3,147 in April 2025, then gave back a large part of those gains. Over the last 52 weeks this MNC pharma stock has swung between Rs 2,088 and Rs 3,121, and the recent one-month rally of about 12% has pulled it back toward the upper half of that range.

Why Did This MNC Pharma Stock Rise 87% in 3 Years?

This MNC pharma stock rose 87% because profit growth finally returned after years of flat sales, margins expanded sharply and the parent began launching its global specialty and oncology drugs in India. A high dividend payout and a debt-free balance sheet kept long-term holders loyal through the volatile patches.

1. Margin Expansion Turned Flat Sales Into Strong Profit Growth

Revenue at this MNC pharma stock has grown slowly, from approximately Rs 3,252 crore in FY23 to Rs 3,822 crore in FY26. Profit grew far faster. Net profit rose from about Rs 611 crore in FY23 to Rs 1,036 crore in FY26, a gain of roughly 70%, because operating profit climbed from Rs 804 crore to Rs 1,309 crore over the same period.

Management credited pricing actions, better field-force productivity, AI-led optimisation and tight cost control. For an MNC pharma stock with modest volume growth, that shift in profitability was the single biggest reason for the re-rating.

Fiscal Year	Revenue	Operating Profit	Net Profit
FY23	Rs 3,252 Cr	Rs 804 Cr	Rs 611 Cr
FY24	Rs 3,454 Cr	Rs 909 Cr	Rs 590 Cr
FY25	Rs 3,749 Cr	Rs 1,179 Cr	Rs 928 Cr
FY26	Rs 3,822 Cr	Rs 1,309 Cr	Rs 1,036 Cr

2. Early Drivers: The FY24 and FY25 Earnings Turnaround

The first leg of the MNC pharma stock rally came in 2024. In May 2024, the company reported a Q4 FY24 standalone profit jump of about 47%, and the GSK Pharma share price surged around 13% in a single session to approximately Rs 2,292.

The second leg followed the December 2024 quarter. Profit rose to around Rs 230 crore from Rs 46 crore a year earlier, revenue grew about 18%, and the EBITDA margin widened by 270 basis points. The MNC pharma stock jumped about 31% in seven trading sessions in February 2025, and by April 2025 it was trading at a record high.

3. Specialty and Oncology Launches From the Parent

The parent's global portfolio is now reaching Indian patients through this MNC pharma stock. Respiratory biologic Nucala and inhaler Trelegy have gained traction, and in August 2025 the company entered oncology with Jemperli for endometrial cancer and Zejula for ovarian cancer. These innovative products made up about 7% of sales in Q1 FY27, up from 4% a year earlier.

More launches are lined up, including the blood cancer drug Blenrep and the RSV vaccine Arexvy. This pipeline gives the MNC pharma stock a growth story that a portfolio of mature antibiotics alone could not provide.

4. Vaccines and Adult Immunisation

Shingrix, the shingles vaccine for older adults, grew around 65% year-on-year in Q1 FY27 and crossed Rs 100 crore in annual sales. Infanrix Hexa and Fluarix Tetra remain leaders in the self-pay paediatric vaccine market. Adult vaccination is still at an early stage in India, which gives this MNC pharma stock a long runway in the segment.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

5. Recent Driver: Q1 FY27 Growth Revival

The latest leg higher came after Q1 FY27 results on 3 August 2026. Revenue grew about 16.5% after roughly eight quarters of subdued growth, and the MNC pharma stock gained around 21% in the month that followed, reaching approximately Rs 2,999 by 20 August.

Management of the MNC pharma stock guided for double-digit revenue growth with flat margins in FY27. The top five promoted general medicine brands, including Augmentin and T-Bact, grew faster than their markets, with Augmentin up 12.8% and T-Bact up 17.9%.

Q1 FY27 Financials of the MNC Pharma Stock

For this MNC pharma stock, the June 2026 quarter showed healthy year-on-year growth, though it was softer than the seasonally strong December and March quarters. Consolidated revenue came in at approximately Rs 938 crore and net profit at Rs 237 crore.

Metric	Q1 FY27 (Jun 2026)	Q4 FY26 (Mar 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue	Rs 938 Cr	Rs 995 Cr	Rs 805 Cr	Up 16.5%
Operating Profit	Rs 296 Cr	Rs 351 Cr	Rs 251 Cr	Up 18%
Operating Margin	31%	35%	31%	Flat
Net Profit	Rs 237 Cr	Rs 278 Cr	Rs 205 Cr	Up 16%
EPS	Rs 14.00	Rs 16.40	Rs 12.10	Up 16%

Gross margin expanded by about 80 basis points to 65.1%, while the EBITDA margin improved by around 30 basis points to 31.5%. Standalone profit grew faster, at about 24% to Rs 253 crore. For an MNC pharma stock that spent years with low single-digit sales growth, a mid-teens revenue print is what investors had been waiting for.

Valuation and Shareholding of the MNC Pharma Stock

The valuation is rich. At the 10 September close, this MNC pharma stock trades at a PE of about 45.7 times trailing earnings and roughly 21 times book value. The premium is backed by an ROE of about 45.6%, an ROCE of about 61.4% and a balance sheet that is practically debt-free.

Metric	Value
Current Price (10 Sep 2026)	Rs 2,841
Market Cap	Rs 48,125 Cr
52-Week High / Low	Rs 3,121 / Rs 2,088
PE (Trailing)	45.7
Price to Book	About 21
ROE	45.6%
ROCE	61.4%
Dividend Yield	About 2%

The shareholding pattern of the MNC pharma stock is steady. The parent holds a fixed 75%, and domestic institutions ticked up slightly in the June 2026 quarter. Foreign institutions also added back after two quarters of small trims.

Holder	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoter	75.00%	75.00%	75.00%	75.00%
FIIs	4.79%	4.63%	4.62%	4.79%
DIIs	7.75%	7.70%	7.68%	7.81%
Public	12.45%	12.67%	12.69%	12.42%

With only 25% of shares in free float, the MNC pharma stock can move sharply on modest institutional buying or selling. The company also pays out most of its profit, with a final dividend of Rs 57 per share for FY26.

What Are the Key Risks for This MNC Pharma Stock?

The biggest risk for this MNC pharma stock is valuation. At around 45 times trailing earnings and about 35 times FY27 estimates, a lot of future growth is already in the price. Any slowdown could trigger a sharp correction, as it did after the April 2025 peak.

Sales growth at this MNC pharma stock has been weak for years. Revenue grew only about 2% in FY26, and five-year sales growth has been in low single digits. The Q1 FY27 revival needs to hold for several quarters before it can be called a trend.

Price controls are a constant threat for any MNC pharma stock in India. Several of the company's older antibiotic and vaccine products fall under drug price regulation, and any expansion of the controlled list could hurt margins. Supply disruptions also affected product availability during FY26.

Dependence on the parent is a double-edged factor. The launch pipeline, royalty terms and product transfers are decided by GSK plc, and minority shareholders have limited say in those choices. The high payout of more than 90% of profit also leaves little cash for acquisitions.

Finally, the weak one-year return of 9.15% shows how quickly sentiment can turn. The share spent much of the past year below its 2025 high, and the MNC pharma stock ranks 75th of 101 on a one-year basis.

Download the Univest iOS App or Univest Android App to track the GSK Pharma share price live

GSK Pharma Share: Analyst View

Analysts agree on the growth recovery at this MNC pharma stock but are divided on the price. A domestic brokerage kept a Neutral rating after Q1 FY27, projecting an earnings CAGR of about 18% through FY28 but seeing limited upside from current levels. Another domestic brokerage has an Add rating, citing the strength of the innovative portfolio.

GSK Pharma Share Price Target

The most recent verified GSK Pharma share price target is Rs 2,870, set by a domestic brokerage on 4 August 2026 with a Neutral rating. That target is only about 1% above the latest GSK Pharma share price of Rs 2,841, which explains the cautious stance.

Beyond this, no other verified brokerage GSK Pharma share price target for FY27 is available. Traders are watching the 52-week high of Rs 3,121 and the record high near Rs 3,147 as resistance, while the early-August level near Rs 2,660 and the 52-week low of Rs 2,088 act as reference levels below.

If revenue growth stays in the mid-teens and new launches such as Blenrep and Arexvy scale up, analysts may revise their targets upward. If growth slips back to low single digits, the MNC pharma stock could de-rate toward lower multiples.

Conclusion

This MNC pharma stock has delivered 87.41% in three years because profit grew much faster than sales, margins expanded and the parent brought its specialty, oncology and vaccine brands to India. The Q1 FY27 revival in revenue growth has given the MNC pharma stock a fresh leg higher after a weak year.

The GSK Pharma share price now trades close to the latest brokerage target and at a premium valuation, so the risk-reward is more balanced than it was in 2023. Investors tracking this MNC pharma stock should watch whether double-digit growth holds, how new launches ramp up and how the stock behaves near its Rs 3,121 to Rs 3,147 resistance zone.

Frequently Asked Questions

Which MNC pharma stock has risen 87% in 3 years?

Ans. GlaxoSmithKline Pharmaceuticals Ltd (NSE: GLAXO) has delivered a 3-year return of 87.41% as of 10 September 2026. It ranks 49th among 101 NSE stocks in that period.

What is the GSK Pharma share price today?

Ans. The GSK Pharma share price closed at approximately Rs 2,841 on 10 September 2026, down about 1.57% for the day. Its 52-week range is Rs 2,088 to Rs 3,121.

Why did the GSK Pharma share rise over three years?

Ans. The rise came from strong profit growth, as net profit grew from about Rs 611 crore in FY23 to Rs 1,036 crore in FY26. New specialty, oncology and vaccine launches and a revival in revenue growth in Q1 FY27 also helped.

What is the GSK Pharma share price target?

Ans. A domestic brokerage set a GSK Pharma share price target of Rs 2,870 with a Neutral rating on 4 August 2026. That is only about 1% above the 10 September close.

What were GSK Pharma's Q1 FY27 results?

Ans. Consolidated revenue rose about 16.5% to Rs 938 crore and net profit rose about 16% to Rs 237 crore. The EBITDA margin improved slightly to around 31.5%.

Is GSK Pharma debt-free?

Ans. Yes, this MNC pharma stock is practically debt-free. It also reports an ROE of about 45.6% and an ROCE of about 61.4%, and pays out most of its profit as dividends.

Who owns GlaxoSmithKline Pharmaceuticals?

Ans. The UK parent GSK plc and its group entities hold 75% of the company. Domestic institutions hold about 7.81% and foreign institutions about 4.79% as of June 2026.

What are the risks of investing in this MNC pharma stock?

Ans. The key risks are a high PE of about 45.7, historically slow sales growth and exposure to drug price controls. The stock has also been volatile, returning only 9.15% over one year.